Special TAC Call 2022-10-17: 5-Whys for Drug Bug, and O3 Release process


Dear all, On this week’s Monday TAC call we have some main agenda items:

  1. Formally confirm the backporting policy for Platform as described here
  2. 5-Whys Retrospective on how this drug-order bug was missed until now, and how we can improve accordingly.
  3. Agree on vision and next steps for the O3 Release process and “Quality Gates” (see diagram & discussion here).

To join: When: Monday at 4pm UTC / 9am PST / 12pm EST / 6pm CEST / 7pm EAT / 9:30pm IST

Where: Launch Meeting - Zoom

CC: @burke @mksd @mksrom @ibacher @dkayiwa @aojwang @mogoodrich @mseaton @eudson & please CC others you think would be interested.

For your discussion regarding the drug-order bug, I want to stress the importance of quality assurance testing from a clinical perspective. Grace and I talked about this bug extensively last week, and the truth is a bug of this level could actually seriously harm patients. The success of the health programs that rely upon our software is based on end users ability to trust OpenMRS and to trust the data that is displayed in front of them. These bugs have serious consequences to that trust. We have come a long ways in our accountability for our software and increasing trust with our end users, but I encourage us to think about ways we can iterate in our QA efforts here and do better at that clinical testing that is needed for trusting our software for decision making. Here’s an article I use with my students for thinking through the implications of clinical testing in an EMR:

@Paul @burke